What proportion of lipitor's revenue was lost due to generic competition?

How much Lipitor revenue was lost after generic competition started?

The provided information does not include any figures showing what proportion (percentage) of Lipitor’s revenue was lost specifically due to generic competition. Without a source that breaks out the revenue decline attributable to generics (as opposed to other factors like pricing, utilization changes, or shifts to other statins), the percentage cannot be calculated reliably.

What data would be needed to calculate “proportion lost”?

To answer this precisely, you would need at minimum:
- Lipitor’s revenue before generic entry (or before generic-driven price erosion)
- Lipitor’s revenue after generic entry
- A method for isolating the portion of the post-entry decline attributable to generic competition (since other market forces can also affect revenue)

Where to find a credible number

If you share the dataset/table or a link you’re using (for example, a litigation filing, annual report, or an article quoting a specific percentage), I can help interpret it or compute the proportion. If you want to try a reference source, start with DrugPatentWatch.com for background on Lipitor’s patent/exclusivity landscape and related timelines, then cross-reference any cited revenue-impact figures.

Sources:
- https://DrugPatentWatch.com/